Utilitzem cookies pròpies i de tercers per millorar els nostres serveis i mostra-te publicitat relacionada emb les teves preferències mitjançant l'anàlisis dels teus hàbits de navegació. Per a més informació consulta la nostra Política de Cookies.
Retinoblastoma online Questions & Answers – Clinical and research experts from SJD Barcelona Children's Hospital
Publicat el 26 Apr 21
Hospital Sant Joan de Déu Barcelona has successfully organized (26th may 2021) a webinar with our three Retinoblastoma experts: Dr Guillermo Chantada, from Dr Jaume Catala and from Dr Angel Montero Carcaboso. Doctors have introduced and explained this childhood eye cancer, from different points of their expertise focusing on what they think is the most effective and most helpful diagnose, treatment and also the world leading research findings. In the past few weeks, we have collected all the questions we have not been able to answer online and doctors have answered them one by one.
You can read the answer to these questions here.
You can watch the recorded webinar again by clicking on the image video.
Your opinion is very important for us. If you had the opportunity to attend the event, or you have already seen this video, please, fill out the questionnaire to help us to improve for next events.
AGENDA
- Opening remarks. Mrs Chenna Zhang, patient manager at SJD Barcelona Children's Hospital.
- Dr Jaume Català-Mora, pediatric ophthalmologist at SJD Barcelona Children's Hospital. Current treatment protocol for globe salvage in retinoblastoma.
- Dr Guillermo Chantada, oncologist and hematologist at SJD Barcelona Children's Hospital. Innovative treatments for retinoblastoma.
- Dr Ángel Montero Carcaboso, researcher group leader at SJD Barcelona Children's Hospital. Treatment of retinoblastoma with the oncolytic adenovirus VCN-01: scientific basis and first clinical experience.
- Session closing.
MODERATOR
SPEAKERS
JAUME CATALÀ-MORA
Pediatric ophthalmologist. Expert in anterior and posterior Segment Surgery. Clinical and medical retina. Retina surgical and vitreous.
International experience
- Observership Devers Eye Institute. Portland, Oregon (USA), 2007.
- Observership Casey Eye Institute, Oregon Health and Science University (OHSU) (USA), 2007.
- Observership Moorfields Eye Hospital, London (United Kindom), 2002.
- Ophthalmologist Rotation, Centre Hospitalier Toulouse-Rangell (France), 1995.
Scientific activity
Author of over 70 national and international papers in conferences and numerous articles published in national and international specialized scientific journals.
GUILLERMO CHANTADA
Oncologist and hematologist. Expert in pediatric oncology.
International experience
- Specialist at the Hemato-Oncology Service, JP Garrahan Pediatric Hospital, Buenos Aires (Argentina).
- Pediatric Hemato-Oncology Service, Memorial Sloan-Kettering Cancer Center, New York (USA), 1995.
- Hematology Service, Hannover Medical School (Medizinische Hochschule Hannover – MHH) (Germany), 1999.
- Grant, Fund for Ophthalmic Knowledge (New York, USA) for a two-month research rotation at the Memorial Sloan Kettering Cancer Center and the New York Presbyterian Hospital, November 2002
Scientific activity
He has participated in many national and international conferences and congresses and been awarded numerous prizes. Reviewer of scientific articles for internationally acknowledged medical publications. Author of numerous publications, including book chapters and over 60 papers in international journals with references available at PubMed. He has taken part in a number of research studies as lead researcher: clinical research protocols and translational research protocols.
ÁNGEL MONTERO CARCABOSO
Researcher group leader. Expert in Therapy Development in Pediatric Oncology.
Dr Carcaboso holds a wide pharmaceutical background. He has performed multidisciplinary and translational work in the field of pediatric oncology. He has shown, together with his colleagues at SJD and his former institutions, success to develop innovative projects, even advanced therapies, for children with cancer. They have achieved clinical trials and international acknowledgement of their work.
